Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hadi Dourra

Internal Medicine Redford, MI Medical Doctor

NPI 1003975517 CMS profile 136434

27144 Joy Rd, Redford, MI 48239

Open in the dashboard

General payments

$5,717

352 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hadi Dourra of Redford, MI is reported in the CMS Open Payments database as having received $5,717 across 352 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,703 92
2024 General $1,032 70
2023 General $807 59
2022 General $745 44
2021 General $826 51
2020 General $267 17
2019 General $338 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hadi Dourra
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Hadi Dourra were reported at $1,703. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Hadi Dourra Internal Medicine median Middle half National median
2019 $338 $159 $48–$570 $163
2020 $267 $119 $33–$402 $114
2021 $826 $135 $37–$521 $132
2022 $745 $141 $42–$496 $149
2023 $807 $149 $45–$519 $160
2024 $1,032 $154 $47–$537 $164
2025 $1,703 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $766 37 payments
  2. GlaxoSmithKline, LLC. $637 55 payments
  3. AbbVie, Inc. $577 43 payments
  4. Lilly USA, LLC $541 34 payments
  5. Novo Nordisk Inc $476 31 payments
  6. ITI, Inc. $344 21 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $315 19 payments
  8. Pfizer Inc. $308 16 payments
  9. E.R. Squibb & Sons, L.L.C. $219 15 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $174 11 payments
  11. Other $1,360 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,717 352 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $473 44 payments
  2. Ozempic $368 24 payments
  3. RYBELSUS $352 23 payments
  4. FARXIGA $328 11 payments
  5. VRAYLAR $314 27 payments
  6. LINZESS $274 8 payments
  7. CAPLYTA $264 17 payments
  8. NURTEC ODT $226 12 payments
  9. JARDIANCE $223 14 payments
  10. ELIQUIS $202 14 payments
  11. Other $4,321 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

9,105

Median for Internal Medicine: 777

Drug cost

$1,450,877

Median for Internal Medicine: $73,373

Branded share of claims

27.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Potassium Generic 137 $286,459
Ozempic Semaglutide Brand 107 $112,361
Januvia Sitagliptin Phosphate Brand 118 $108,165
Jardiance Empagliflozin Brand 96 $97,598
Farxiga Dapagliflozin Propanediol Brand 119 $89,286
Mounjaro Tirzepatide Brand 85 $87,789
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 106 $73,065
Eliquis Apixaban Brand 74 $61,344
Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate Brand 36 $57,381
Trulicity Dulaglutide Brand 52 $56,336

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$180,024

Of which drugs: $2,954

Medicare patients

384

Average age 71

Services billed

2,435

205 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 48%
Ischemic heart disease 43%
Arthritis 41%
Chronic kidney disease 35%
Heart failure 34%
COPD 34%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 18 18 $1,473
Injection, ketorolac tromethamine, per 15 mg J1885 Office 14 20 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $76
  • Boehringer Ingelheim Pharmaceuticals, Inc. $48
$124 96 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $103
$103 106 —
ARISTADA
  • Alkermes, Inc. $73
$73 — —
VRAYLAR
  • AbbVie, Inc. $73
$73 19 —
AREXVY
  • GlaxoSmithKline, LLC. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

352 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record